Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
lonoctocog alfa
- Development stage
- Approved
- Lead developer
- CSL Behring
- Modality
- Recombinant Proteins and Enzymes
- Administration
- Intravenous
01
Overview
Lonoctocog alfa is a recombinant human coagulation factor VIII (FVIII) used for the treatment and prevention of bleeding in patients with hemophilia A. It is a single-chain FVIII molecule with a truncated B-domain, allowing covalent linkage between the heavy and light chains, which improves its stability and affinity for von Willebrand factor (VWF). This enhanced VWF binding stabilizes FVIII in circulation and protects it from degradation. Lonoctocog alfa replaces the missing or deficient endogenous FVIII in hemophilia A patients, thereby restoring effective hemostasis by enabling normal blood clotting. It is indicated for both on-demand treatment of bleeding episodes and prophylaxis to prevent bleeds across all age groups[1][3][5][6][7].
- Brand names
- Afstyla
- Other names
- antihemophilic factor (recombinant), single chainrecombinant single-chain FVIIIB-domain truncated recombinant FVIII
02
Targets
Coagulation Factor IXaBB-031 (Von Willebrand factor)F8 (Coagulation Factor VIIIa)
Beyond the preview
Go deeper on lonoctocog alfa.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on lonoctocog alfa.